Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.
Apellis Pharmaceuticals, Inc. reports news on its commercial-stage biopharmaceutical business centered on complement science and C3-targeting medicines. Recurring updates cover SYFOVRE, a pegcetacoplan injection for geographic atrophy secondary to age-related macular degeneration, and EMPAVELI, pegcetacoplan for rare diseases including paroxysmal nocturnal hemoglobinuria and rare kidney indications.
Company news also includes product revenue updates, ophthalmology and nephrology data presentations, pipeline references tied to complement biology, board and governance changes, investor conference participation, collaboration matters, and corporate-status developments involving strategic transactions and related shareholder communications.
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) has completed its underwritten public offering, raising approximately $402.5 million through the sale of 4,007,936 shares of common stock priced at $63.00 per share, along with pre-funded warrants for 2,380,956 shares. The offering includes an additional 833,333 shares due to underwriters' full exercise of their option. The funds will support Apellis' commitment to developing innovative therapies. J.P. Morgan, Goldman Sachs, and Evercore served as joint book-running managers for the offering, which was facilitated under an automatically effective shelf registration statement.
Apellis Pharmaceuticals (Nasdaq: APLS) announced the pricing of its public offering of 3,174,603 shares of common stock at $63.00 per share, and 2,380,956 pre-funded warrants at $62.9999 each, totaling approximately $350 million gross proceeds before deductions. The offering is set to close on February 27, 2023, pending customary conditions. J.P. Morgan, Goldman Sachs, and Evercore are the joint book-running managers. The securities are offered under an automatically effective shelf registration statement filed with the SEC. This move aims to bolster Apellis's ability to develop innovative therapies targeting serious diseases.
Apellis Pharmaceuticals has initiated an underwritten public offering of $300 million in its common stock, with the possibility of a 15% over-allotment option for underwriters. The offering is managed by J.P. Morgan, Goldman Sachs, and Evercore, and will occur under an automatically effective shelf registration filed with the SEC on February 22, 2023. The final terms will be disclosed in a prospectus supplement. Apellis, recognized for its advancements in complement medicine, aims to leverage the funds for its ongoing development of therapies targeting critical diseases.
Apellis Pharmaceuticals announced its fourth quarter and full year 2022 financial results, highlighting the FDA approval of SYFOVRE as the first treatment for geographic atrophy due to age-related macular degeneration. The company generated $65.1 million in EMPAVELI U.S. net product revenues for 2022. R&D expenses decreased to $387.2 million, attributed to completed trials and collaborations. However, general and administrative expenses rose to $277.2 million. Apellis reported a net loss of $652.2 million for 2022. The company anticipates launching SYFOVRE in the U.S. by March 2023 and continues to pursue further approvals internationally.
Apellis Pharmaceuticals has announced FDA approval for SYFOVRE™ (pegcetacoplan injection), the first treatment for geographic atrophy (GA)/b) secondary to age-related macular degeneration (AMD). SYFOVRE is designed to slow GA progression, with increasing effects over time, and offers dosing flexibility ranging from every 25 to 60 days. The drug has a well-demonstrated safety profile following approximately over 24 months. SYFOVRE is expected to be available by early March through specialty distributors. A marketing application is also under review in Europe, with a decision expected in early 2024.
Apellis Pharmaceuticals (Nasdaq: APLS) announced the grant of equity awards to 8 new employees, effective February 1, 2023. These equity inducement awards were granted outside the 2017 Stock Incentive Plan, under the terms of the 2022 Inducement Stock Incentive Plan. The new hires received options for 18,435 restricted stock units (RSUs), which will vest over four years, contingent upon their continued employment. This initiative aims to attract talent and support the company's growth in the biopharmaceutical sector, focusing on developing therapies for rare, retinal, and neurological diseases.
Apellis Pharmaceuticals (APLS) announced the appointment of Caroline Baumal, M.D., as the new chief medical officer, replacing Federico Grossi, M.D., Ph.D., who will assist during the transition until February 28, 2023. Dr. Baumal brings over 25 years of experience in retina research and patient care, crucial for the upcoming launch of pegcetacoplan for geographic atrophy (GA). The company is preparing for a PDUFA date next month, with pegcetacoplan showing promise in clinical trials as the first treatment for GA, a leading cause of blindness affecting millions.
Apellis Pharmaceuticals (Nasdaq: APLS) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 9:00 a.m. PT / 12:00 p.m. ET. The event will be available via a live webcast on the company’s website, with a replay accessible for 90 days post-event. Apellis is recognized for pioneering complement medicine, having launched the first approved targeted C3 therapy, and is focused on developing transformative treatments for rare retinal and neurological diseases.
Apellis Pharmaceuticals (Nasdaq: APLS) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency for pegcetacoplan, targeting geographic atrophy (GA) due to age-related macular degeneration (AMD). This application is based on Phase 3 DERBY and OAKS trials, showing significant reductions in GA lesion growth over 24 months. If approved, pegcetacoplan would be the first treatment for GA in Europe. The FDA review is pending with a PDUFA date of February 26, 2023, highlighting the urgency for treatment in a disease that severely impacts more than five million globally.
Apellis Pharmaceuticals (Nasdaq: APLS) recently announced the approval of equity inducement awards for two new employees, effective December 1, 2022. The awards include options to purchase 8,790 restricted stock units (RSUs), which will vest annually at 25% over four years, contingent on the employees' continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is aimed at attracting talent by offering competitive compensation through equity opportunities. Apellis remains committed to advancing innovative therapies in complement medicine.